Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Tabletop particle accelerator could transform medicine and materials science 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
India Budget 2026: Modi Government Eyes Reforms Amid Global Uncertainty and Fiscal Pressures 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
